CeriBell (NASDAQ:CBLL) Given Average Recommendation of "Buy" by Brokerages

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $32.50.

CBLL has been the topic of several research analyst reports. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company.

CeriBell Stock Up 0.2 %

Shares of CBLL stock traded up $0.04 during trading hours on Tuesday, reaching $16.32. 208,040 shares of the company traded hands, compared to its average volume of 270,817. The stock's 50-day moving average price is $18.85. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, equities research analysts expect that CeriBell will post -2.46 earnings per share for the current fiscal year.

Insider Activity at CeriBell

In other news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction that occurred on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the transaction, the chief executive officer now directly owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 24,700 shares of company stock valued at $372,434.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently bought and sold shares of the business. FMR LLC purchased a new stake in shares of CeriBell during the 4th quarter valued at about $128,120,000. TPG GP A LLC bought a new stake in CeriBell during the fourth quarter worth approximately $102,677,000. Red Tree Management LLC purchased a new stake in CeriBell during the fourth quarter valued at approximately $57,083,000. Yu Fan bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in shares of CeriBell in the 4th quarter worth approximately $28,160,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.